Role of Phase 0 trials in drug development. - Wikidata - awgldk - TriplyDB

Role of Phase 0 trials in drug development.

Role of Phase 0 trials in drug development.

http://www.wikidata.org/entity/Q39934032

about

Antidotes, antibody-mediated immunity and the future of pharmaceutical product development.Intra-Target Microdosing - A Novel Drug Development Approach: Proof of Concept, Safety, and Feasibility Study in Humans.

P2860

Q38071898-C30E6F3C-036C-4E7A-8737-2C0A2F2C45BD Q41369567-540C5696-59BC-4F22-957F-D2E79FB676EB

P2860

Role of Phase 0 trials in drug development.

http://www.wikidata.org/entity/Q39934032

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Role of Phase 0 trials in drug development.

@en

Role of Phase 0 trials in drug development.

@nl

type

label

Role of Phase 0 trials in drug development.

@en

Role of Phase 0 trials in drug development.

@nl

prefLabel

Role of Phase 0 trials in drug development.

@en

Role of Phase 0 trials in drug development.

@nl

P1433

Q39934032-5B0449EE-385A-416F-8440-037F7851C652

P1476

Q39934032-98A6A414-4659-48FD-A0B4-C16D17F4AA8B

P2093

Q39934032-1093D8A4-654B-46F3-A60C-C9E57B5AB40C

Q39934032-D3CE77A7-C658-474E-9499-08B995957CB9

P2860

Q39934032-0556FFCE-0384-4CF3-B61E-C937EE204FED

Q39934032-074BE749-1435-4C91-B95D-6654A628D86E

Q39934032-0A24FCA7-F5A2-4E63-8EB8-E2584F1D05CD

Q39934032-0F13306E-3CA2-4B54-A167-C8F1AE0EEC76

Q39934032-3EF48501-7900-4EF0-8375-D1EBFAC36D2E

Q39934032-4BC518BB-9961-421E-B098-4BA96930DF8C

Q39934032-526188F9-0B89-4162-B5E0-958FDEF8AFB3

Q39934032-5AC44D88-A502-4027-BDC4-B17BB9FBA307

Q39934032-61E122D7-E909-4B2D-977B-10263DF87A41

Q39934032-68BF97A9-9B3C-4B31-B296-72C2B5C9C2E8

P304

Q39934032-720C7F08-1457-4809-909C-55310B656961

P31

Q39934032-FC8C2303-4229-438A-B2C6-2A364985D4DF

P356

Q39934032-FB939E28-83F3-4FDC-98B5-FA6C28D6F840

P433

Q39934032-4F14F21E-2438-488C-B93C-38EE17F30D7A

P478

Q39934032-C9A76DC9-50FE-405D-BF99-4B6F31B15DD8

P577

Q39934032-371A670F-344F-4AA0-85A6-67E21EA0F603

P698

Q39934032-7A301796-EC0C-49BC-B776-633B1BEE27E8

P356

P1433

Future Medicinal Chemistry

P1476

Role of Phase 0 trials in drug development.

@en

P2093

James H Doroshow

http://www.w3.org/2001/XMLSchema#string

Shivaani Kummar

http://www.w3.org/2001/XMLSchema#string

P2860

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Can the pharmaceutical industry reduce attrition rates?

Poly(ADP-ribose): novel functions for an old molecule

Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group.

The PARP superfamily.

PARP inhibitors for cancer therapy.

Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies.

The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials

P304

1375-1380

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4155/FMC.09.117

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2009-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21426052

http://www.w3.org/2001/XMLSchema#string